Skip Navigation

Evan Jacob Lipson, M.D.

Headshot of Evan Jacob Lipson
  • Associate Professor of Oncology

Specializes in: Adults (18+ years)



Clinical Trials, Immunotherapy, Medical Oncology, Melanoma more

Research Interests

Melanoma; Immunotherapy

Request an Appointment

Insurance Information

Main Phone


Outside of Maryland

Request Appointment

International Patients

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8893 | Fax: 410-955-8587

Sibley Memorial Hospital

Appointment Phone: 202-660-6500
5255 Loughboro Road, NW
1st Floor
Washington, DC 20016 map
Fax: 202-660-6501


Dr. Lipson is a cutaneous oncology and clinical immunotherapy specialist at Johns Hopkins. Dr. Lipson is a member of the Kimmel Cancer Center's comprehensive Melanoma Program. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research.  He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center.

Dr. Lipson's primary research interest is in early-phase clinical trials for patients with melanoma and other skin cancers.  As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease.  Dr. Lipson is a principal or co-investigator on multiple trials, involving partners from both industry and academia, which focus on the clinical development of antibodies that block the PD-1/PD-L1 pathway. Dr. Lipson’s publications include the first description of successful PD-1 re-induction therapy (Clin Can Res 2013), and the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer (JCO 2014, NEJM 2016). 

Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. This trial is the first of its kind and is being activated at several academic cancer centers across the US.

In addition to his research activities, Dr. Lipson is an internationally-recognized educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. more


  • Associate Professor of Oncology

Departments / Divisions

  • Medicine at Sibley Memorial Hospital
  • Oncology - Medical Oncology

Centers & Institutes



  • MD; Icahn School of Medicine at Mount Sinai (2005)


  • Medicine; Johns Hopkins University School of Medicine (2008)


  • Oncology; Johns Hopkins University School of Medicine (2011)

Board Certifications

  • American Board of Internal Medicine (Medical Oncology) (2010)

Research & Publications

Clinical Trials

View Dr. Lipson's current research trials at Sibley Memorial Hospital here.

Selected Publications

View all on PubMed

Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19:462-468.

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016.

Lipson EJ, Bagnasco SM, Moore J,Jr, Jang S, Patel MJ, Zachary AA, Pardoll DM, Taube JM, Drake CG. Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. N Engl J Med. 2016;374:896-898.

Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32:e69-71.

Rowe SP, Luber B, Makell M, Brothers P, Santmyer J, Schollenberger MD, Quinn H, Edelstein DL, Jones FS, Bleich KB, Sharfman WH, Lipson EJ. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol. 2018 Aug 16.

Activities & Honors


  • American Society for Clinical Oncology


  • Society for Melanoma Research


  • Society for Immunotherapy of Cancer


  • Eastern Cooperative Oncology Group


Videos & Media

Recent News Articles and Media Coverage

New Cancer treatments have perplexing side effects, The Washington Post , Jan 2, 2018

How Does Immunotherapy Work?, Melanoma Research Alliance, Feb. 2, 2016

In The Beginning, Hopkins Medicine, Fall 2014

Keytruda Just One of a New Class of Cancer Drugs to Restart the Immune System, Healthline News, Sept. 10, 2014

New Skin Cancer Drug Approved, CNN, Jan. 31, 2012

'Seize the Days' Project Documents a Life with Cancer, WAMU 88.5, Jan. 6, 2012

Giving Patients a Way to Share Their Stories, Cancer.Net, April 4, 2011

Is this you? Edit Profile
back to top button